{"id":"azd0156","_chembl":null,"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"ATM kinase","explanation":"AZD0156 blocks ATM kinase activity, which plays a critical role in detecting and repairing DNA double-strand breaks. By inhibiting ATM, the drug prevents cancer cells from repairing DNA damage, potentially enhancing the effects of DNA-damaging therapies and leading to cancer cell death.","oneSentence":"AZD0156 is a selective inhibitor of ataxia telangiectasia mutated (ATM) kinase, a key DNA damage response protein."},"_scrapedAt":"2026-03-28T04:57:37.950Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123164,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"ceralasertib","brand":null,"company":"AstraZeneca","rationale":"ATR kinase inhibitor targeting DNA damage response pathway"},{"name":"berzosertib","brand":null,"company":"Merck KGaA","rationale":"ATR kinase inhibitor for DNA damage response in cancer"},{"name":"elimusertib","brand":null,"company":"Repare Therapeutics","rationale":"ATR inhibitor targeting DNA damage repair mechanisms"}],"description":"AZD0156 is an investigational small molecule inhibitor developed by AstraZeneca for the treatment of cancer. The drug is currently in Phase 1 clinical trials to evaluate its safety, tolerability, and preliminary efficacy in patients with advanced solid tumors and hematologic malignancies.","indications":{"approved":[{"status":"investigational","condition":"Advanced solid tumors","patientPopulation":"Adult patients with advanced malignancies"},{"status":"investigational","condition":"Hematologic malignancies","patientPopulation":"Adult patients with blood cancers"}]},"trialDetails":[{"nctId":"NCT02588105","phase":"PHASE1","title":"Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-11-10","conditions":"Advanced Solid Tumours","enrollment":84}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":48,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"AZD0156","genericName":"AZD0156","companyName":"AstraZeneca","companyId":"astrazeneca","firstApprovalDate":"","aiSummary":"AZD0156 is being studied in a clinical trial for the treatment of advanced solid tumours. The trial is assessing the safety and preliminary efficacy of AZD0156 alone or in combination with other anti-cancer treatments, such as olaparib and irinotecan.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}